Grey Matter Neurosciences, a medical technology company developing innovative transcranial focused ultrasound (tFUS) systems for use in medical devices and drug-device combinations, today confirmed the appointment of Tom Wilder to its Board of Directors.
With nearly 35 years of experience in the development and commercialization of advanced medical technologies – particularly in the neurological space – Mr. Wilder brings deep strategic insight and operational expertise to Grey Matter. His career reflects a longstanding commitment to improving patient outcomes and advancing breakthrough therapies for the brain.
“Tom’s appointment is a tremendous boon for Grey Matter Neurosciences,” said Dr. Jeffrey Coull, Founder and CEO. “His technical leadership, proven success at companies, including Neuros and Sequent Medical, and his deep understanding of neuromodulation align perfectly with our mission. We’re excited to work with him as we scale our tFUS platform to address age-related brain diseases.”
About Tom Wilder
- Over three decades of leadership in medical device innovation, including as CEO of Neuros Medical, where he advanced a novel neuromodulation therapy for chronic pain that recently received FDA pre-market approval
- Led Sequent Medical, developer of a groundbreaking treatment for cerebral aneurysms, through its successful acquisition by Terumo Medical
- During an 11-year tenure at Medtronic, led key strategic finance functions and later oversaw its endovascular stent graft business unit
- Demonstrated expertise across development, regulatory strategy, manufacturing, and global market launch – particularly in the neurology therapeutic area
- Currently serves as CEO of VS3 Medical, a neurovascular company, as well as on the Board of Directors of Penumbra, Inc. (NYSE: PEN)
“I am thrilled to join Grey Matter Neurosciences at this exciting juncture,” said Mr. Wilder. “Their tFUS technology is poised to revolutionize how we understand and treat age-related brain conditions. I look forward to working alongside the leadership team to accelerate R&D, facilitate regulatory progress, and bring these potentially life-changing therapies to patients as soon as possible.”
About Grey Matter Neurosciences
Grey Matter Neurosciences is a Toronto-based medical technology advancing novel devices and drug-device combinations to treat age-related diseases of the brain. Founded in 2024, the company is built on groundbreaking transcranial focused ultrasound technology developed by Dr. Kullervo Hynynen and his team at Sunnybrook Research Institute. To date, Grey Matter has secured nearly $20M in equity-based and non-dilutive funding.
Media Contact
Jeffrey Coull
Founder and CEO
Grey Matter Neurosciences
info@greymatterneurosciences.com